Trials / Conditions / Hematopoietic Stem Cell Transplant (HSCT)

Hematopoietic Stem Cell Transplant (HSCT)

12 registered clinical trials studyying Hematopoietic Stem Cell Transplant (HSCT) — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Venetoclax Combined With Azacitidine for Consolidation Therapy in AML NCT07425782	The First Affiliated Hospital of Soochow University	Phase 2
Recruiting	Ivosidenib as Post-HSCT Maintenance for AML NCT06707493	Massachusetts General Hospital	Phase 2
Recruiting	PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Sync NCT06665100	Pulmotect, Inc.	Phase 2
Recruiting	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation NCT06702111	The University of Hong Kong	—
Completed	Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index NCT05524246	Children's Hospital Medical Center, Cincinnati	Phase 1
Terminated	Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients W NCT04673175	Weill Medical College of Cornell University	Phase 4
Active Not Recruiting	Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia NCT07232953	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Phase 2
Terminated	Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant NCT04908735	Children's Hospital Medical Center, Cincinnati	Phase 2
Recruiting	TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients NCT04098445	Children's Hospital Medical Center, Cincinnati	—
Unknown	Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Unde NCT04712435	Instituto Brasileiro de Controle do Cancer	Phase 2
Completed	Developing Self-Management Interventions After HCT NCT03710031	University of Florida	—
Completed	Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS NCT02626715	Randy Windreich	Phase 2